Joel Gallant
Overview
Explore the profile of Joel Gallant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
5398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raben D, Jakobsen M, Trajanovska J, Kowalska J, Vassilenko A, Dragas S, et al.
PLoS One
. 2025 Jan;
20(1):e0316794.
PMID: 39879174
Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care with HIV, on antiretroviral treatment (ART) and virologically suppressed (VS), with the aim of monitoring...
2.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, et al.
Clin Infect Dis
. 2024 Apr;
79(5):1242-1257.
PMID: 38663013
Background: Mortality among people with human immunodeficiency virus (HIV) declined with the introduction of combination antiretroviral therapy. We investigated trends in mortality in people with HIV from 1999 through 2020....
3.
Alvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, et al.
Clin Infect Dis
. 2023 Apr;
77(4):593-605.
PMID: 37052343
Background: There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluated the impact of different baseline...
4.
Maggiolo F, Rizzardini G, Molina J, Pulido F, De Wit S, Vandekerckhove L, et al.
HIV Med
. 2022 May;
24(1):27-36.
PMID: 35527425
Objectives: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective treatment for HIV-1 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking. The primary 24-week and secondary 48-week...
5.
Sax P, Andreatta K, Molina J, Daar E, Hagins D, Acosta R, et al.
AIDS
. 2022 Apr;
36(11):1511-1520.
PMID: 35466963
Objective: We investigated the prevalence of preexisting M184V/I and associated risk factors among clinical trial participants with suppressed HIV and evaluated the impact of M184V/I on virologic response after switching...
6.
Byonanebye D, Polizzotto M, Neesgaard B, Sarcletti M, Matulionyte R, Braun D, et al.
HIV Med
. 2022 Mar;
23(8):895-910.
PMID: 35233903
Objective: To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease...
7.
Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, Gunthard H, De Wit S, et al.
Lancet HIV
. 2021 Sep;
8(11):e711-e722.
PMID: 34555326
Background: Weight gain effects of individual antiretroviral drugs are not fully understood. We investigated associations between a prespecified clinically significant increase (>7%) in body-mass index (BMI) and contemporary antiretroviral use....
8.
Maggiolo F, Rizzardini G, Molina J, Pulido F, De Wit S, Vandekerckhove L, et al.
Infect Dis Ther
. 2021 Mar;
10(2):775-788.
PMID: 33686573
Introduction: We report the 48-week results of an ongoing study to assess the efficacy and safety of switching older people with HIV to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). Methods: This was a...
9.
Neesgaard B, Mocroft A, Zangerle R, Wit F, Lampe F, Gunthard H, et al.
PLoS One
. 2020 Dec;
15(12):e0243625.
PMID: 33382756
Objectives: To compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-life setting. Methods: Using logistic...
10.
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
Olender S, Perez K, Go A, Balani B, Price-Haywood E, Shah N, et al.
Clin Infect Dis
. 2020 Jul;
73(11):e4166-e4174.
PMID: 32706859
Background: We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and...